NCT00002338View on ClinicalTrials.gov

The Safety and Effectiveness of 935U83 in HIV-Infected Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Raluridine

Trial Locations (7)

15261

Univ of Pittsburgh Med School, Pittsburgh

20007

Georgetown Univ Med Ctr, Washington D.C.

27710

Duke Univ Med Ctr, Durham

32751

Goodgame Med Group, Maitland

45267

Univ of Cincinnati / Holmes Hosp, Cincinnati

46202

Indiana Univ Hosp, Indianapolis

94103

ViRx Inc, San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Glaxo Wellcome

INDUSTRY

NCT00002338 - The Safety and Effectiveness of 935U83 in HIV-Infected Patients | Biotech Hunter | Biotech Hunter